Iovance Biotherapeutics, Inc. (IOVA) News
Filter IOVA News Items
IOVA News Results
|Event/Time||Symbol||Company||News Detail||Start||End||Change||POWR Rating|
|Loading, please wait...|
Latest IOVA News From Around the Web
Below are the latest news stories about Iovance Biotherapeutics Inc that investors may wish to consider to help them evaluate IOVA as an investment opportunity.
Iovance Biotherapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Thursday, August 6, 2020
SAN CARLOS, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter 2020 financial results on Thursday, August 6, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. EDT. To participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 7875997. The live webcast can be accessed in the Investors section of the Company’s website at www.iovance.com. The archived webcast will be available for one year.About Iovance Biotherapeutics, Inc. Iovance Biotherapeutics aims to improve pati...
Guru ups bet in biotech focused on ear-related disorders Continue reading...
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
After rumors swirled about a potential acquisition, it now appears the biopharma is transitioning to commercial operations as a standalone company.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) $IOVA #Stocks #biopharmaceutical #MedicalStocks #Healthcarenews Buy at $23, Sell at $47 IOVA’s tumour infiltrating lymphocyte (TIL) therapy showed promising efficacy in metastatic melanoma Iovance BiotherapeuticsTicker: NASDAQ:IOVAPrice: $28.69Recommendation: Buy Sector News It is sad, but cancer is a pervasive illness that has affected 16% of the population of the world. In order […]
It has been widely accepted that tumor cells are antigenic, due to the somatic mutations which alter their protein structure/expression profile and being recognized as “foreign” by the immune system. Further, it has long been known that TILs are common among various cancer types and their presence usually correlates to...
Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer. TIL cells are extracted from a patient’s own tumor tissue, expanded through a proprietary process, and infused back into the patient.
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Iovance Biotherapeutics (IOVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The shares of common stock issued and sold in the offering include 2,540,322 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less the underwriting discounts and commissions. Iovance intends to use the proceeds from this offering to fund the expansion of its organization to support the potential commercial launch of lifileucel for advanced melanoma and LN-145 for advanced cervical cancer, to initiate a program directed at registration of Iovance’s tumor infiltrating lymphocyte therapies in non-small cell lung cancer, to continue support of ongoing commercial manufacturing activities, and for the development of Iovance’s IL-2 analog, IOV-3001, and for other general corporate purposes.